<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors></authors><secondary-authors><author><style face="normal" font="default" size="100%">,</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Correction: Healthcare costs associated with short-acting β2-agonists in asthma: observational UK SABINA study</style></title><secondary-title><style face="normal" font="default" size="100%">BJGP Open</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024-08-20 00:00:00</style></date></pub-dates></dates><elocation-id><style  face="normal" font="default" size="100%">BJGPO.2024.9997</style></elocation-id><doi><style  face="normal" font="default" size="100%">10.3399/BJGPO.2024.9997</style></doi><volume><style face="normal" font="default" size="100%"></style></volume><issue><style face="normal" font="default" size="100%"></style></issue><abstract><style  face="normal" font="default" size="100%">In the Research article by Attar-Zadeh et al. Healthcare costs associated with short-acting β2-agonists in asthma: observational UK SABINA study BJGP Open 2023; DOI: https://doi.org/10.3399/BJGPO.2023.0015, the healthcare resource utilisation costs were extrapolated to the overall Integrated …</style></abstract></record></records></xml>